Phakic IOLs = long-term failures?

Article

Phakic intraocular lenses (IOLs) have failed to live up to their promise, according to an opinion expressed at this year's meeting of the French Society of Ophthalmology (SFO).

Phakic intraocular lenses (IOLs) have failed to live up to their promise, according to an opinion expressed at this year's meeting of the French Society of Ophthalmology (SFO).

Joseph Colin, MD, president of the SFO, urged caution about the hype surrounding newer models of phakic IOLs, stressing that, despite positive short-term results, these lenses are essentially unproven until long-term results are known.

Dr Colin cited the inauspicious recent history of angle-supported phakic IOLs, including the 2007 market withdrawals of the NewLife (IOLTech/Carl Zeiss Meditech), Vivarte (IOLTech/Carl Zeiss Meditech) and Icare (Corneal) lenses, which were withdrawn because of significant endothelial cell loss, to reinforce his argument. In these cases, complications presented two to three years postoperatively, necessitating explantations in a statistically significant percentage of patients.

Despite these complications, the popularity of phakic IOLs continues to grow. Dr Colin believes phakic IOLs still have a place (particularly among thin cornea patients for whom laser refractive surgery is not indicated) and measures are in place to improve long-term success and avoid complications: postoperative endothelial cell evaluations have now been mandated to allow for timely explantations, for instance, and stringent criteria for patients receiving angle-supported lenses (anterior chamber depth ≥3 mm; corneal diameter ≥11 mm; IOL power ≤20 D).

In spite of these new measures, and the promising short-term results from lenses including the AcrySoft phakic IOL (Alcon) - not just in terms of minimal endothelial cell loss but also in terms of adverse events, stability of refraction and visual acuity - Dr Colin continued to advocate vigilance, saying, "Current models must not be used until the results of retrospective studies provide more reliable information on the safety of these implants."

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.